Uniqure N.V. (QURE)

$14.47 -0.37 (-2.49%)
Market Cap 904.48M
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -883.33%
Debt to Equity Ratio -12.96
Volume 1,028,867
Avg Vol 1,137,044
Day's Range N/A - N/A
Shares Out 54.87M
Stochastic %K 4%
Beta 0.14
Analysts Strong Sell
Price Target $34.73

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
Latest News on QURE
uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

Sep 5, 2025, 4:57 PM EDT - 10 days ago

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Sep 5, 2025, 7:05 AM EDT - 11 days ago

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 6 weeks ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA RCKT

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:07 PM EDT - 6 weeks ago

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Jul 29, 2025, 7:05 AM EDT - 7 weeks ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:05 AM EDT - 2 months ago

uniQure to Announce Second Quarter 2025 Financial Results

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 11, 2025, 8:00 AM EDT - 3 months ago

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Jun 2, 2025, 7:05 AM EDT - 3 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 28, 2025, 4:56 AM EDT - 3 months ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:16 PM EDT - 4 months ago

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025, 7:05 AM EDT - 4 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

May 8, 2025, 5:16 AM EDT - 4 months ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 4 months ago

uniQure to Announce First Quarter 2025 Financial Results

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

Apr 21, 2025, 1:56 AM EDT - 5 months ago

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Apr 19, 2025, 8:31 AM EDT - 5 months ago

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

Apr 17, 2025, 10:27 AM EDT - 5 months ago

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Apr 17, 2025, 7:17 AM EDT - 5 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Feb 27, 2025, 7:05 AM EST - 7 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V.: A Potential Huntington's Play

Feb 26, 2025, 1:47 AM EST - 7 months ago

uniQure N.V.: A Potential Huntington's Play

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 20, 2025, 3:07 PM EST - 7 months ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 1:04 PM EST - 7 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 7, 2025, 9:12 AM EST - 7 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Feb 3, 2025, 7:05 AM EST - 8 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 30, 2025, 7:37 AM EST - 8 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

Jan 8, 2025, 7:05 AM EST - 8 months ago

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

Jan 7, 2025, 4:49 PM EST - 8 months ago

uniQure Announces Proposed Public Offering

Final Trade: DVN, QURE, GOOGL, DFH

Dec 30, 2024, 6:31 PM EST - 9 months ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Dec 10, 2024, 7:05 AM EST - 10 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 21, 2024, 7:05 AM EST - 10 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:05 AM EST - 11 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Oct 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Sep 23, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 6, 2024, 3:03 AM EDT - 1 year ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Aug 1, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

Jul 23, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

What Led To A 150% Rise In UniQure Stock In A Week?

Jul 12, 2024, 8:00 AM EDT - 1 year ago

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 9, 2024, 1:48 PM EDT - 1 year ago

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

Jul 9, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Jul 1, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Jul 1, 2024, 7:05 AM EDT - 1 year ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

Jun 3, 2024, 7:05 AM EDT - 1 year ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 7, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Feb 28, 2024, 7:05 AM EST - 1 year ago

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure: The Valuation Got More Attractive

Feb 1, 2024, 2:25 PM EST - 1 year ago

uniQure: The Valuation Got More Attractive

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Dec 19, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Dec 11, 2023, 7:30 PM EST - 1 year ago

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

Nov 29, 2023, 7:05 AM EST - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease